07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

Emulsified Influenza HA Vaccine regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Emulsified Influenza HA Vaccine, an H5N1 adjuvanted prophylactic pandemic influenza vaccine , from Kaketsuken and partner GlaxoSmithKline. The intramuscular vaccine uses the EB66 cell line from...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

Daiichi Sankyo said its Kitasato Daiichi Sankyo Vaccine Co. Ltd. subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine. Kitasato Daiichi received a grant...
00:56 , Jun 20, 2013 |  BC Extra  |  Company News

Daiichi seeking Japanese approval of pandemic flu vaccine

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said its Kitasato Daiichi Sankyo Vaccine Co. Ltd. subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine ....
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken (formerly the Chemo-Sero-Therapeutic Research Institute) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based, H5N1 adjuvanted pandemic influenza vaccine. In 2009,...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Cell culture-based pandemic influenza vaccine: Phase III started

Vivalis S.A. (Euronext:VLS, Nantes, France) said GlaxoSmithKline and Kaketsuken began a Japanese Phase III trial to evaluate a cell culture-based pandemic flu vaccine in healthy adults. In 2009, GlaxoSmithKline and Kaketsuken (formerly the Chemo-Sero-Therapeutic Research...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Cell culture based pandemic influenza vaccine: Phase II started

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken began in April a Japanese Phase II trial to evaluate a cell culture-based pandemic flu vaccine. In 2009, GlaxoSmithKline and Kaketsuken (formerly the Chemo-Sero-Therapeutic Research Institute) partnered to...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Iomai, GlaxoSmithKline, Novartis, U.S. Department of Health and Human Services infectious news

HHS awarded $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GSK will receive $63.3 million over five years for vaccine R&D, and the U.S. government also may opt...
01:14 , Jan 18, 2007 |  BC Extra  |  Top Story

HHS awards $132.5M for avian flu vaccines

The U.S. Department of Health and Human Services awarded a total of $132.5 million to three companies to develop adjuvant-based vaccines and adjuvants for H5N1 avian influenza. GlaxoSmithKline (LSE:GSK; GSK) will receive $63.3 million over...